Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants

Human Vaccines & Immunotherapeutics · Available online 2 Jul 2026 · In press · DOI 10.1080/21645515.2026.2676381

Free full text

Authors (10)

Xiaoqiang Liu, Yulin Jing, Xiuqing Wang, Fei Yang, Ana Cristy Ugarte Guzmán, Dunson Ejedepang, Jieqiong Hu, Keruo Liu, Yassmine Ammiche, Md Ahsan Habib

Abstract

Rotavirus (RV) is a leading cause of diarrhea-related morbidity and mortality among children under 5 y globally, accounting for approximately one-third of childhood diarrhea cases in China. Vaccination is the most effective strategy for RV prevention. Rotarix, a liquid RV vaccine with a 2-dose schedule, has been modified to exclude porcine circovirus (PCV) components. This study evaluated the immunogenicity and safety of Rotarix PCV-free vs Rotarix in healthy Chinese infants. In this Phase III, observer-blinded, randomized, multicenter study, infants aged 6–16 weeks were randomized to receive two oral doses of either vaccine (Rotarix PCV-free or Rotarix) 1-month apart. Primary endpoints were seroconversion rates (SCRs) and geometric mean concentrations (GMCs) of serum anti-RV IgA antibodies 1-month post-Dose 2. Non-inferiority was defined as a 95% CI lower limit (LL) for both SCR ≥ −10% and GMC ratio ≥ 0.67. Safety was assessed by monitoring solicited adverse events (AEs) within 14 d post-vaccination, unsolicited AEs within 31 d, and serious AEs (SAEs) throughout the study. Of 2000 randomized participants, 96.8% (Rotarix PCV-free) and 96.6% (Rotarix) received both doses. SCR: 84.9% (Rotarix PCV‑free) vs 88.7% (Rotarix); difference −3.73% (95% CI − 6.93, −0.55; p = .0317), met non‑inferiority ≥−10%. GMC ratio did not meet non‑inferiority: ratio 0.71 (95% CI 0.60–0.84; p < .0001), 95% CI LL < prespecified 0.67. The most common systemic AE was cough/runny nose (Rotarix PCV-free 30.6% vs Rotarix 25.4%); SAEs occurred in 26.1% and 25.2% of participants, respectively, with none deemed vaccine-related. Rotarix PCV-free demonstrated non-inferior SCRs vs Rotarix. Both vaccines showed comparable safety profiles.ChinaDrugTrials.org registration: CTR2023189.EudraCT: 2020-000972-38.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2026

Citation

Liu, X., Jing, Y., Wang, X., et al. (2026). Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2026.2676381

Related articles